Industry-Funded Gambling Harm Research: Why the Data Argument Keeps Winning

The recurring fight over gambling-harms research funding is less mysterious than it gets made out to be. In practice, the industry already holds the data researchers need, and the cleaner question is how to fund treatment first and research second without turning every grant into a conspiracy theory.

1. The basic case for industry involvement is straightforward: the gambling business has the data. That matters because quality data is one of the main inputs in any serious piece of research, and anonymised player data can help researchers study harm without the operator standing over their shoulder in the lab.
2. The source argues for a specific order of priorities: treatment first, research second. That is a useful distinction for PSPs, acquirers, and operators watching regulatory expectations, because “funding gambling harms work” is not one bucket. Treatment funding goes to real-world support; research funding goes to finding out what is actually happening and why.
3. The text also points out that gambling addiction treatment is often underfunded and sometimes folded into broader addiction services, even though the overlap with drug abuse is limited. Drug abuse can be a contributor to gambling addiction, but that does not mean the same treatment model fits both problems.
4. On paper, criticism of industry-funded research usually comes down to influence risk. The counterargument here is that a contribution can be ring-fenced for a specific purpose, such as research into gambling addiction in the disabled population, and the funding source can then step back while the work is carried out and published later.
5. The source’s broader point is practical rather than rhetorical: in every country with a legal market, the industry should pay towards treatment and research. It also says data sharing without caveats would be a meaningful contribution, because researchers cannot do much with bad or partial data, and the industry cannot improve the conversation if it withholds the raw material.

The catch for high-risk operators is that this is not really a branding exercise. If a market expects industry money to support harm research and treatment, the useful questions are who controls the funds, what data gets shared, and whether the process is separated enough from commercial decision-making to be credible.